Movement Alert｜10x Genomics Falls 5.15% in Pre-Market Trading, Fred Hutchinson Collaboration Fails to Lift Sentiment

Market Focus10-08 20:03

On October 8, 10x Genomics fell 5.15% in pre-market trading, trading at $72.21 per share with turnover of $102.69 million.

The company's announcement of a multi-project research collaboration with Fred Hutchinson Cancer Center did not bolster market confidence. The partnership will use Flex Apex and Xenium platforms to identify treatment response biomarkers in advanced bladder cancer and assess single-cell analysis for residual disease detection in acute myeloid leukemia, but the news failed to offset prevailing negative sentiment.

Broader pressure persists across the life sciences tools sector, with Thermo Fisher Scientific down 0.31%, Danaher down 0.29%, Illumina down 1.58%, and Tempus AI down 2.77%.

10x Genomics, Inc. develops instruments, consumables, and software for analyzing biological systems, including single cell and spatial genomics solutions for academic and biopharmaceutical institutions.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment